Medscape | Boxed Warning on HBV Reactivation for Blood Cancer Drugs Medscape A boxed warning about the risk for reactivation of hepatitis B virus (HBV) infection in patients who once had the virus has been added to the product labeling for 2 drugs used in the treatment of hematological malignancies, rituximab (Rituxan) and ... FDA Strengthens Warnings for Arzerra and Rituxan |
